DCP

Star Wars™ 'March to May the 4th' kicks off in New York City, delights fans with new products and a stunning light show

Retrieved on: 
Friday, March 22, 2024
Hyperspace, Sun, Disneyland Resort, Phantom, Star Wars, High Republic, TIE, Star, Sale, STAR, The Acolyte, Dairy Farmers, Fifth Avenue, Specialty store, WHTZ, Star Wars Hyperspace Mountain, Heroes, The Home Depot, Sith, PopSockets, Force, Coffee, Lucasfilm, The Lego Group, LEGO, Panasonic, Series, Senior, Disney Store, Book, DCP, IHeartRadio, Empire State Building, IHeartMedia, Walt Disney World, Star Wars: Galaxy's Edge, Light, Hollywood studios, Disney Consumer Products, Walt Disney, Multimedia, Collection, Fireworks

NEW YORK, March 21, 2024 /PRNewswire/ -- The Star Wars March to May the 4th campaign began today with new product announcements including toys, apparel, accessories, collectibles and more. The march started with a takeover of the iconic Empire State Building that included a lighting ceremony, fan experiences, window displays and more — culminating in a showstopping dynamic light show displayed on the façade of the world-famous New York landmark.

Key Points: 
  • The takeover of the Empire State Building includes interactive photo moments, which highlight new Star Wars consumer products in window and observatory deck displays.
  • On the iconic 86th Floor Observatory , Star Wars fans can pose with a life-size Funko POP!
  • Additionally, Hasbro and Amazon have teamed up to create a Star Wars experience with something for every Star Wars fan on the first floor of the Empire State Building.
  • Star Wars Celebration 2025: Star Wars Celebration, the Ultimate Star Wars Fan Event, is taking place April 18-20, 2025, in Japan.

409A Direct Launches the First Online Platform for Nonqualified Deferred Compensation Plan Design and Implementation

Retrieved on: 
Wednesday, March 20, 2024
SMB, Luigi, DCP

TAMPA, Fla., March 20, 2024 /PRNewswire/ -- 409A Direct today announced its launch, giving small- to medium-sized businesses access to a technology platform for creating and implementing nonqualified deferred compensation plans (NQDCPs) online.

Key Points: 
  • TAMPA, Fla., March 20, 2024 /PRNewswire/ -- 409A Direct today announced its launch, giving small- to medium-sized businesses access to a technology platform for creating and implementing nonqualified deferred compensation plans (NQDCPs) online.
  • "Our groundbreaking technology platform provides small- to medium-sized businesses [SMBs] with the ability to design, financially model and implement nonqualified deferred compensation plans at a lower price point and more quickly than the traditional route," explained 409A Direct founder and CEO Todd Mezrah.
  • "409A Direct enables SMBs to enhance their executive compensation programs by building robust and compliant plans in less than a third of the time it typically takes."
  • As a result, we're seeing more SMBs looking to offer deferred compensation plans as a benefit for key employees—and our one-of-a-kind platform gives them a secure online option to implement a plan quickly and economically."

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Retrieved on: 
Wednesday, February 21, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Large intestine, Bangladesh Technical Education Board, Cancer, HNPCC, Medicine, B cell, TTY, DCP, FDA, Safety, Hereditary nonpolyposis colorectal cancer, National Cancer Institute, Vaccine, Risk, Biliary tract, Stomach, Antigen, Ureter, Patient, Pancreas, NK, Clinical trial, Protein, Diagnosis, Translational research, Colorectal cancer, Adenoviridae, Immune system, Brain, Pharmaceutical industry

The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.

Key Points: 
  • The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.
  • Each of the three vaccines in Tri-Ad5 targets different proteins associated with precancer and cancer cells.
  • The vaccine combination is studying whether activation of dendritic cells and training the immune system to recognize those proteins will destroy the precancer cells before the cancer occurs.
  • Safety and efficacy of these investigational agents have not been established by any Health Authority, including the FDA.

Questions and answers on the European Union framework for (traditional) herbal medicinal products, including those from a ‘non-European’ tradition

Retrieved on: 
Sunday, March 10, 2024
Well, DER, Fungus, Capsule, TUR, Interest, Animal, Part, Exercise, Database, Viral, Hepatitis, Powder, Collection, Directive, Union, Nutrient, DSM-IV codes, Volume, CTD, Legislation, Literature, Fermentation, Diabetes, Pharmacopoeia, Inhalation, Committee, Monograph, NTA, WEU, DCP, AIDS, See, Mineral, Marketing, Safety, Plant, MRA, Autoimmunity, Directive 2001/83/EC, GMP, Documentation, Seed, Heart failure, Distillation, CHMP, MRP, European Medicines Agency, Guideline, Disorder, Mutual, Convention, State, Tablet, Community, Clinical trial, Rapporteur, European Commission, Woman, Medication package insert, Vitamin, Quality, Authority, GACP, SAWP, Pharmacovigilance, Civil service commission, HMPS, Science, Health, Bibliography, Section 4, Infection, Kampo, Commission, Abbreviation, Pathology, Prescription, Human, Medication, Reproduction, EMA, NCA, Chapter One, EDQM, TAM, European Pharmacopoeia, European Economic Area, Food, Regulation (European Union), COM, TCM, Administration, Mutual recognition, Procedure, Medicine, Herbal, Answer, Q&A, HIV, EudraLex, Cancer, Public, Medicinal plants

1

Key Points: 
    • 1
      Committee on Herbal Medicinal Products (HMPC)

      Questions & Answers on the European Union framework
      for (traditional) herbal medicinal products, including those
      from a ?non-European? tradition

      Table of Content
      1.

    • European Pharmacopoeia

      SAWP

      Scientific Advice Working Party

      SmPC

      Summary of Product Characteristics

      THMP

      Traditional Herbal Medicinal Product

      TUR

      Traditional Use Registration

      WEU

      Well-Established Use

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Terminology of herbal medicinal products (Q&A 1-4)

      Question 1
      What are herbal substances, herbal preparations, and herbal medicinal products?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 4
      Are food supplements regulated under the European Union (EU) pharmaceutical legislation
      for (traditional) herbal medicinal products ((T)HMPs)?
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Regulation of herbal medicinal products in the European Union (Q&A 511)

      Question 5
      Where to find the pharmaceutical legislation and dossier requirements for herbal medicinal
      products (HMPs), including traditional herbal medicinal products (THMPs), in the European
      Union (EU)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • These countries have,
      through the EEA agreement, adopted the complete Union acquis on medicinal products and are
      consequently parties to the Union procedures.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Specific provisions for traditional herbal medicinal products (Q&A 1221)

      Question 12
      Which indications can be granted for traditional herbal medicinal products (THMPs)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Nov. 2023
      Answer 17

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 29
      Does the Committee on Herbal Medicinal Products (HMPC) hold a specific database on
      (registered) authorised (traditional) herbal medicinal products ((T)HMPs)?
    • Discussion with Member States intended to be

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

National DCP Hires Juan Joachin to Serve as Chief Financial Officer

Retrieved on: 
Tuesday, February 27, 2024
CFO, Senior, ITESM, DCP, Marketing, Dominoes, Growth, Columbia Business School, IMD, Treasury, Dunkin, Inspire Brands, University, Organization, NDCP, Financial management, Institute of Management Accountants, Management

ATLANTA, Feb. 27, 2024 /PRNewswire/ -- National DCP (NDCP), the $3 billion supply chain management company serving Dunkin' franchisees, has hired Juan Joachin to serve as Chief Financial Officer (CFO). Joachin reports directly to Chief Executive Officer Stephen Down.

Key Points: 
  • ATLANTA, Feb. 27, 2024 /PRNewswire/ -- National DCP (NDCP), the $3 billion supply chain management company serving Dunkin' franchisees, has hired Juan Joachin to serve as Chief Financial Officer (CFO).
  • Joachin reports directly to Chief Executive Officer Stephen Down.
  • "With more than thirty years of outstanding international financial leadership, Joachin brings tremendous knowledge of Dunkin' and the members we serve to this role," said Stephen Down, CEO.
  • As the Chief Financial Officer, Joachin is responsible for the successful execution of NDCP's day-to-day financial and internal audit functions to support our long-term strategic goals, enabling growth, service level delivery and profitability.

Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP™ (vigabatrin oral solution)

Retrieved on: 
Thursday, February 15, 2024
Health, Consumer, Neurology, Children, Baby, Maternity, Pharmaceutical, Biotechnology, CMS, DCP, Spasm, Patient, Reference, Epilepsy, RMS, Medication, Epileptic spasms, Medical device, Pharmaceutical industry

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.

Key Points: 
  • Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.
  • "We are incredibly pleased with the positive outcome supporting the approval of VIGZIP™ in several key European markets.
  • This achievement serves as a testament to our dedication to developing innovative solutions for unmet medical needs in rare pediatric diseases.
  • Pyros remains committed to expanding access to VIGZIP™ in other additional territories around the world,” stated Michael Smith, Chief Executive Officer of Pyros.

Fujifilm and Decentralized Pictures Announce the 2024 / 2025 Fujifilm Aspiring Filmmakers Award Series

Retrieved on: 
Monday, February 12, 2024
American Zoetrope, ARV, Francis Ford, DCP, Calendar, Life, Film industry

The 2024 / 2025 Fujifilm Aspiring Filmmakers Award Series of quarterly awards will be hosted on the DCP platform, where DCP’s community of film fans and enthusiasts will have the opportunity to vote to choose filmmakers who will be awarded FUJIFILM digital cameras with lens kit products, as well as production support and mentorship.

Key Points: 
  • The 2024 / 2025 Fujifilm Aspiring Filmmakers Award Series of quarterly awards will be hosted on the DCP platform, where DCP’s community of film fans and enthusiasts will have the opportunity to vote to choose filmmakers who will be awarded FUJIFILM digital cameras with lens kit products, as well as production support and mentorship.
  • Fujifilm Aspiring Filmmakers Award Series, Phase One (2024): U.S.-resident filmmakers will be invited to submit proposals on the DCP platform for three- to five-minute short films based on a creative prompt unique to each quarter in 2024.
  • Fujifilm Aspiring Filmmakers Award Series, Phase Two (2025): In Spring 2025, the 12 Phase One Award projects will be entered into a second creative award on the DCP platform to be rated by the DCP community.
  • “We’re thrilled to launch this award series with a partner that shares our dedication to championing aspiring filmmakers, and excited to see which projects our community chooses to support on the DCP platform.”

HealthyWomen Joins the Flow Collective, SHE Media's Roster of Premium Independent Publishers Dedicated to Health and Wellness

Retrieved on: 
Friday, January 5, 2024
Dick Clark Productions, PMC, SHE Media, Woman, Journalism, Health, DCP, Collective, HealthyWomen, The Hollywood Reporter, Variety, Media, Flow, Penske Media Corporation, Pharmaceutical industry

Anchored by SHE Media flagship brand Flow, the Flow Collective is a first-of-its-kind curation of highly credible and trusted publishers and creators in the health and wellness vertical.

Key Points: 
  • Anchored by SHE Media flagship brand Flow, the Flow Collective is a first-of-its-kind curation of highly credible and trusted publishers and creators in the health and wellness vertical.
  • The addition of HealthyWomen to the Collective continues SHE Media's long-standing commitment to serving women's health through impactful content, engaging events, meaningful partnerships and journalistic integrity.
  • "For more than 35 years, HealthyWomen has been dedicated to engaging, educating, and empowering women on their health journeys," said Beth Battaglino, RN-C, CEO HealthyWomen.
  • Together with SHE Media, we can finally change the narrative that women's health is just gynecological or reproductive health.